| 1 |
29662630 | Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer. | 2018 Mar 23 |
1 |
| 2 |
27025703 | Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors. | 2016 Mar 30 |
4 |
| 3 |
27196768 | EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines. | 2016 Jul |
2 |
| 4 |
23844038 | Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions. | 2013 |
2 |